COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (NASDAQ:CLN) today reported that on April 11, 2008 at the meeting of the International Congress of Hyperthermic Oncology, in Munich, Germany, Dr. Zeljko Vujaskovic, Associate Clinical Professor at Duke University, presented early data from 13 patients in a Phase I dose escalation and safety study using ThermoDox to treat patients with recurrent breast cancer on the chest wall. He reported that at doses 20mg/m2 and 30mg/m2 patients showed satisfactory toxicity and promising clinical activity. He further explained that two of the patients treated at the 30mh/m2 dose level have shown a complete local response in the treated area. The study has now enrolled four patients at the 40mg/m2 dose level of which three patients have been treated. Data on the local effect is awaited. These preliminary data are subject to further confirmation at time of study completion.
